Regeneron Pharmaceuticals, Inc.

In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...

CMN Weekly (2 February 2024) - Your Weekly CRISPR...

CMN Weekly

Feb. 2, 2024

Some of the best links we picked up around the internet

CMN Weekly (6 October 2023) - Your Weekly CRISPR...

Oct. 6, 2023

Some of the best links we picked up around the internet

Clinical Update: CRISPR Therapy for Transthyretin...

Mar. 2, 2022

In this week's update, we provide news about Intellia Therapeutics' and Regeneron's ongoing Phase 1 trial for NTLA-2001 in transthyretin amyloidosis....

CRISPR Clinical Trial Roundup: Rare Diseases

Feb. 16, 2022

In this week's clinical trial update, we summarise the ongoing in vivo CRISPR clinical trials for three distinct rare genetic diseases: hereditary...